The number of anti-vaccine bills filed in Texas has risen, yet many Texans support vaccine policy. Fellow Kirstin R.W. Matthews and nonresident scholar Rekha Lakshmanan examine the stakes of legislative engagement in public health initiatives and provide a call to action for Texans to embrace public health as an act of freedom.
Will OPEC+ begin to reverse large production cuts at its June 1 meeting? In large part, it will depend on whose oil market outlook is closest to the mark, writes Mark Finley, fellow in energy and global oil. He examines several forecasts and outlines the issues in a new commentary.
Mark Finley explains the cost-benefit analysis behind the Saudi government's recent move to pause plans to increase spare oil production capacity — and why spare capacity still equates to power in the oil market.
When the OPEC+ group met last week and agreed to extend production cuts through the first quarter of 2024, the market was unimpressed. Fellow in Energy and Global Oil, Mark Finley, outlines the meeting’s outcomes and discusses why the recent agreement “could augur a year of difficult meetings ahead” in a new commentary.
Drug companies that bypass distributors and offer generics directly to patients, like the Mark Cuban Cost Plus Drug Company, could disrupt the pharmaceutical supply chain and ultimately save thousands of lives.
